Citadel Advisors LLC
- SEC CIK
- 0001423053
- Latest filing
- Sep 1, 2026
ENGN holding history
enGene Therapeutics Inc. in every 13F filed by Citadel Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ENGN overviewAll 13F holders of ENGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 717,686
- Value
- $1.24M
- % of portfolio
- <0.1%
- Quarters held
- 8
- Since Q4 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 717,686 | $1.24M | <0.1% | +563,744+366.2% | Added | Holders |
| Q1 2026 | 153,942 | $1.05M | <0.1% | +128,559+506.5% | Added | Holders |
| Q4 2025 | 25,383 | $229.2K | <0.1% | −32,987−56.5% | Reduced | Holders |
| Q3 2025 | 58,370 | $398.7K | <0.1% | +35,327+153.3% | Added | Holders |
| Q2 2025 | 23,043 | $83.9K | <0.1% | +23,043 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −613,292−100.0% | Sold out | Holders |
| Q2 2024 | 613,292 | $5.78M | <0.1% | −190,886−23.7% | Reduced | Holders |
| Q1 2024 | 804,178 | $13.6M | <0.1% | +784,121+3,909.5% | Added | Holders |
| Q4 2023 | 20,057 | $185.1K | <0.1% | +20,057 | New | Holders |